21 May 2009
Efficacy and safety of steroid – free immunosuppression with tacrolimus and daclizumab in liver transplant recipients. Six years follow-up in a single centre
B Foroncewicz, K Mucha, E Ryszkowska, J Ziółkowski, M Krawczyk, L PączekAnn Transplant 2009; 14(1): 76-76 :: ID: 880479
Abstract
Background: Corticosteroid-free maintenance immunosuppression eliminates the well-known corticosteroid-related side effects and may help to improve long-term outcome.
Material/Methods: We investigated whether a corticosteroid-free tacrolimus
(Tac) in combination with daclizumab (Dac) induction therapy, provides an
adequate immunosuppression after liver transplantation (OLTx). This 6-years,
single centre, retrospective study involved 25 liver transplant recipients randomized to a Tac/Dac regimen (n=7) or a Tac/corticosteroids (Tac/CS)
regimen (n=18), according to the protocol of the MASTER study. Patient's and graft's survival, incidence of acute rejection and diabetes mellitus, liver and kidney function as well as BMI were compared between the groups. In order to quantify the therapy-related adverse events the total length of hospitalization was analysed.
Results: Demographic data including age, gender and ischemic time were similar in both groups. No signifi cant difference was found in patient and graft
survival in both treatment arms (71.5% in Tac/Dac and 94.5% in Tac/CS, p=NS). The incidence of biopsy-proven acute rejection was 16% in Tac/CS and 14% in Tac/Dac group (P=NS). Renal and liver function was also similar in both groups. However, compared with the Tac/CS regimen, a significantly reduced incidence of new-onset diabetes mellitus (DM) (14% vs. 22%, p<0.05) was found with steroid-free immunosuppression. Also the blood pressure (BP) and BMI were significantly lower in Tac/Dac patients (p<0.05). Total time of hospitalization did not differ significantly between the groups (46.1 days/person in Tac/CS vs. 55.1 in Tac/Dac, p=NS)
Conclusions: Corticosteroid-free immunosuppression with a Tac/Dac regimen
is as effective at yielding good patient and graft survival as a standard double
regimen of Tac/CS. The lower incidence of DM and better BP and BMI control in Tac/Dac group may indicate higher safety of Tac/Dac treatment.
Keywords: Immunosuppression, Liver Transplantation, clinical outcome
In Press
15 Mar 2024 : Review article
Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighti...Ann Transplant In Press; DOI: 10.12659/AOT.941185
18 Mar 2024 : Original article
Does Antibiotic Use Increase the Risk of Post-Transplantation Diabetes Mellitus? A Retrospective Study of R...Ann Transplant In Press; DOI: 10.12659/AOT.943282
20 Mar 2024 : Original article
Transplant Nephrectomy: A Comparative Study of Timing and Techniques in a Single InstitutionAnn Transplant In Press; DOI: 10.12659/AOT.942252
28 Mar 2024 : Original article
Association Between FEV₁ Decline Rate and Mortality in Long-Term Follow-Up of a 21-Patient Pilot Clinical T...Ann Transplant In Press; DOI: 10.12659/AOT.942823
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860